Eli Lilly Launches Innovation Hub in Hyderabad!

Eli Lilly Launches Innovation Hub in Hyderabad

Hyderabad, August 4, 2025 – US-based pharmaceutical giant Eli Lilly and Company has officially inaugurated its new Global Capability Centre (GCC) at Gachibowli, Hyderabad. This 220,000 sq ft science and innovation hub is aimed at accelerating the company’s global digital transformation, with the capacity to support innovation across the world. 

Focus Areas & Strategic Priorities

• The Centre, called Lilly Capability Centre India (LCCI) Hyderabad, will expand the company's strengths in:

  • Artificial Intelligence (AI)

  • Automation

  • Cloud Computing

  • Software Product Engineering 

• Designed not as mere back‑office support but as a global nerve‑centre of innovation, connecting and enhancing Eli Lilly’s worldwide operations 

Talent & Employment

• The centre has already onboarded approximately 100 employees, with plans to grow to 1,500 professionals over the next two to three years. 

• Target hires include technology engineers, data scientists, and other skilled professionals, highlighting Hyderabad's access to a deep talent pool. 

Hyderabad: A Life Sciences & GCC Powerhouse

• Telangana CM Revanth Reddy described Hyderabad as a world-class GCC capital, crediting the government’s proactive policies and infrastructure development over the past 20 months. 

• Hyderabad hosts over 2,000 life sciences and pharmaceutical companies, and contributes around 40% of India's pharmaceutical output, with 1 in 3 vaccines globally developed or manufactured here. 

• The state is ambitiously targeting a USD 1 trillion economy by 2034, as part of the larger "Telangana Rising 2047" vision. 

Leadership Statements

• Chief Minister Revanth Reddy:
  “This isn't just another centre—it is the nerve‑centre of Eli Lilly, a brain that will manage and accelerate global operations. You are shaping the future of global healthcare from Hyderabad.” 

• IT & Industries Minister D. Sridhar Babu emphasized the state’s rapid addition of over 70 new GCCs in 2024–25, with a goal to hit 100 in 2025–26, while pointing to infrastructure such as Genome Valley and med‑tech parks as enablers. 

Broader Implications

1. Tech‑Enabled Health Innovation: The Hyderabad site represents a leap forward in deploying digital tools for drug discovery, supply chain optimization, and global service delivery.

2. Job Creation: Projected to create 1,000–1,500 high-tech jobs, boosting local ecosystem while integrating global talent flows.

3. Strengthening Ecosystem: Reinforces Hyderabad as a preferred destination for GCCs of major healthcare, biotech, and IT organizations—solidifying its trajectory as India’s premier life sciences and innovation hub. 

Conclusion

Eli Lilly’s GCC in Hyderabad is more than a corporate expansion. It’s an emblem of Hyderabad’s emergence as a global technology and life sciences hub. With its strategic vision, talent readiness, and thriving ecosystem, Telangana is positioning itself at the forefront of global healthcare innovation. And with ambitious state goals aligned to this ecosystem, LCCI Hyderabad is poised to be a flagship milestone in India’s journey toward becoming a digital life sciences powerhouse.